BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
Researchers from Johns Hopkins Medicine have revealed that a cancer drug could be used to target a Parkinson’s disease (PD)-causing protein that drives the spread of alpha-synuclein, a key hallmark of the neurological condition.
Mab has announced a collaboration and supply agreement with Bristol Myers Squibb (BMS) to assess givastomig in combination with nivolumab plus chemotherapy for advanced gastric and oesophageal cancers.
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3...
Bristol Myers Squibb's immunotherapy combination broke AstraZeneca's three-year overall survival rate record in newly diagnosed liver cancer.
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 2 (Reuters) - Treatment with Bristol Myers Squibb's (BMY.N), opens new tab immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.
BMS secures another EC approval for Opdivo combination
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma